GH Research Reports Full Year 2025 Results, Strong Cash Position, and Targets 2026 Phase 3 Initiation for GH001

summarizeSummary

GH Research PLC reported full-year 2025 financial results, including a widening net loss, but highlighted a strong cash position of $280.7 million and reiterated positive Phase 2b data for GH001, targeting Phase 3 initiation in 2026.

check_boxKey Events

• Full Year 2025 Financial Results

  GH Research reported a net loss of $48.3 million, or $0.79 per share, for the full year 2025, compared to a net loss of $39.0 million, or $0.75 per share, for 2024. Research and development expenses increased to $38.8 million, and general and administrative expenses rose to $22.0 million.

• Strong Cash Position

  The company ended 2025 with a robust cash, cash equivalents, and marketable securities balance of $280.7 million, a significant increase from $182.6 million at the end of 2024, providing substantial operational runway.

• GH001 Phase 2b Data Reiteration

  The filing reiterated strong Phase 2b trial results for GH001 in treatment-resistant depression (TRD), showing a placebo-adjusted MADRS reduction of -15.5 points at Day 8 (p<0.0001) and a 57.5% remission rate at Day 8 versus 0% on placebo. Durable efficacy with a 73% remission rate at six months was also highlighted.

• FDA Clearance and Phase 3 Program Target

  GH001 was cleared by the FDA for U.S. clinical investigation, enabling U.S. subject enrollment. The company is actively seeking FDA alignment on the design of its global Phase 3 pivotal program, targeting initiation for 2026.

auto_awesomeAnalysis

GH Research PLC's 6-K filing provides a comprehensive update on its full-year 2025 financial performance and clinical pipeline. While the company reported a widening net loss, which was previously noted in news alerts, it also highlighted a robust cash position of $280.7 million, significantly extending its operational runway. The filing reiterates strong Phase 2b data for its lead candidate, GH001, in treatment-resistant depression (TRD), emphasizing its potential competitive advantages. Crucially, the company targets the initiation of its global Phase 3 pivotal program for GH001 in 2026, providing a clear forward-looking milestone for investors. This update offers a balanced view of financial health and clinical progress, which is important for a clinical-stage biopharmaceutical company.